Serum leptin in dialysis renal osteodystrophy

Area of Science:

• Endocrinology
• Nephrology
• Bone Metabolism

Background:

• Leptin's potential role in preventing osteoporosis by inhibiting osteoclasia is debated, particularly in males.
• Existing research on leptin's effect on bone mass is contradictory.
• The relationship between serum leptin and renal osteodystrophy in dialysis patients remains unstudied.

Purpose of the Study:

• To investigate the association between serum leptin levels and histomorphometric/histodynamic parameters of bone in hemodialysis patients.
• To explore the correlation of leptin with bone turnover markers and parathyroid hormone (PTH).

Main Methods:

• 46 hemodialysis patients (32 men, 14 women) underwent transiliac bone biopsy with double-tetracycline labeling.
• Serum levels of leptin, PTH (intact and whole), OPG, bone alkaline phosphatase, calcium, phosphate, and vitamin D metabolites were measured.
• Leptin was quantified using radioimmunoassay.

Main Results:

• Serum leptin levels were significantly higher in women than men and correlated positively with BMI.
• Adjusted leptin levels (SDS leptin) showed inverse correlations with PTH1-84, osteoclastic surface (OcS/BS), and osteoclastic number.
• SDS leptin also correlated inversely with mineral apposition rate and positively with OPG levels, with stronger correlations observed in men.

Conclusions:

• Serum leptin levels are linked to both bone resorption and formation, inversely correlating with both processes.
• Decreased osteoclasia with increasing leptin is not mediated by enhanced OPG.
• Elevated serum leptin does not appear to cause low-turnover bone disease in this population.